149246-87-7

Usage

Uses

Used in Medicinal Chemistry:
5-Pyridin-3-yl-2H-pyrazol-3-ylamine is used as a building block in the development of new pharmaceuticals for its potential to contribute to the creation of novel drug candidates with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Pyridin-3-yl-2H-pyrazol-3-ylamine is used as a key intermediate to construct more complex molecules, which can be further utilized in various chemical and pharmaceutical applications.
Used in Agrochemicals:
5-Pyridin-3-yl-2H-pyrazol-3-ylamine may find applications in agrochemicals, where its unique structure could be leveraged to develop new compounds for crop protection or enhancement of agricultural productivity.
Used in Materials Science:
In materials science, 5-Pyridin-3-yl-2H-pyrazol-3-ylamine could be explored for its potential to contribute to the development of new materials with specific properties, such as conductivity, stability, or reactivity, depending on its integration into the material's structure.
The specific applications and properties of 5-Pyridin-3-yl-2H-pyrazol-3-ylamine are likely to be influenced by its chemical structure and the context in which it is used, highlighting the importance of further research and development in these areas.

InChI:InChI=1/C8H8N4/c9-8-4-7(11-12-8)6-2-1-3-10-5-6/h1-5H,(H3,9,11,12)

Upstream product

• 72430-94-5 3-(5-nitro-1⁽²⁾H-pyrazol-3-yl)-pyridine 
• 287493-97-4 (Z)-3-Amino-3-pyridin-3-yl-acrylonitrile 
• 22083-74-5 3-(1-methyl-pyrrolidin-2-yl)-pyridine 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 30510-18-0 nicotinoylacetonitrile 
• 100-54-9 pyridine-3-carbonitrile 
• 93-60-7 methyl 3-pyridinecarboxylate 
• 59-67-6 nicotinic acid 

Downstream Products

• 1269515-40-3 2,6-difluoro-3-(propylsulfonamido)-N-(2-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)benzamide 

Relevant academic research and scientific papers

Synthesis and structure - Activity relationships of quarternary ammonium cephalosporins with 3-pyrazolylpyridium derivatives

Cephalosporins with 3-pyazolylpyridinium at C-3 position, which is supposed to exhibit synergic activity of ceftazidime and cefoselis, were synthesized and their antibacterial activity against Gram-positive and Gram-negative was inspected. (C) 2000 Elsevier Science Ltd. All rights reserved.

Synthesis of Pyrazole Compounds by Using Sonication Method

A simple method for the synthesis of pyrazoles derivatives carried out by cyclization of cyanide with hydrazine hydrate by using sonication method. All the prepared compounds were characterized by 1H, 13C NMR and IR Spectroscopy.

BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is C or N; Y is C or N; Z is CR4 or N; provided that when: (i) X is N, then Y is C; and (ii) X is C, then Y is N and Z is N; and wherein R1, R2/sub

BENZENE SULFONAMIDES AS CCR9 INHIBITORS

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.